Intrasense (FR0011179886 – ALINS), specialist in software solutions
medical imaging and designer of Myrian®informs its shareholders that the Combined General Meeting (ordinary and extraordinary) convened on second notice on July 12, 2022 having been unable to validly deliberate, for lack of quorum,
on the draft resolutions of an extraordinary nature, the shareholders are again convened on 1er September 2022 at 2 p.m. at the registered office of the Company, located at 1231, avenue du Mondial 98 – 34000 Montpellier.
The Extraordinary General Meeting is called to deliberate on the same agenda as that appearing on the initial notice of meeting dated June 10, 2022. The resolutions adopted on second notice are not subject to a vote. Only so-called extraordinary resolutions (No. 11 to 17 and No. 19) are put to the vote.
Pursuant to an order from the President of the Commercial Court of Montpellier dated July 18, 2022, an ad hoc representative has been appointed. In particular, he will be responsible for representing defaulting minority shareholders, and will exercise their voting rights on the basis of two-thirds of positive votes and one-third of negative votes, in order to make his participation in the deliberations neutral, in terms of qualified majority. .
The proxies and postal voting forms returned for the Combined General Meeting of June 27, 2022 (first call) and July 12, 2022 (second call) will remain valid for the Extraordinary General Meeting of June 1, 2022.er September August 2022.
Founded in 2004, Intrasense develops and markets a unique medical device, Myrian®, a software platform facilitating and securing diagnosis, decision-making and therapeutic monitoring. Thanks to Mirian®, more than 1,000 healthcare establishments in 40 countries benefit from a single, integrated platform for reading all types of images (MRI, scanner, etc.). Enriched with expert clinical applications for specific pathologies, Myrian® offers a universal image processing solution that can be integrated into all health information systems. Intrasense has 56 employees, including 16 dedicated to Research and Development. Labeled “innovative company” by the BPI, it has invested more than 10 million euros in Research and Development since its creation.
More information on : http://www.intrasense.fr/fr/.